Nantes, France – February 18, 2022, 6:00 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces the appointment of Alexandre Lebeaut by cooptation as independent director of the Company*.
Alexandre Lebeaut has more than 25 years of rich experience and leadership in innovation, research and development, ranging from preclinical to market, with major successes, particularly in the fields of immunology, oncology, immuno-inflammation and infectious diseases. He has held various international positions, mainly in the United States and in particular within Bluebird Bio, Sanofi, Novartis and Schering Plow Research Institute. More recently, Alexandre Lebeaut was “Executive Vice-President R&D and Chief Scientific Officer” at Ipsen in the United States. He currently leads an American non-profit organization, I-ACT for Children (Institute for Advanced Clinical Trials for Children), based in Maryland and dedicated to the development of pediatric drugs.